Ursodeoxycholic acid sodium(Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

发表于2024年12月10日由上海金畔生物科技有限公司

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ursodeoxycholic acid sodium (Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

Ursodeoxycholic acid (Ursodeoxycholate) sodium 是由肠道细菌转化 (cheno)脱氧胆酸而产生的一种次级胆汁酸，是肠道屏障完整性的关键调节因子，对脂质代谢至关重要。Ursodeoxycholic acid sodium 作为信号分子，通过与胆汁酸激活的受体相互作用发挥作用，包括G蛋白偶联的胆汁酸受体5 (TGR5，GPCR19) 和法尼酯X受体 (FXR)。Ursodeoxycholic acid sodium 可用于多种肝脏和胃肠道疾病的研究。具有口服活性。

Ursodeoxycholic acid sodium Chemical Structure

CAS No. : 2898-95-5

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
500 mg	￥1000	In-stock
1 g	￥1800	In-stock
5 g	￥6300	In-stock
10 g		询价
50 g		询价

* Please select Quantity before adding items.

Ursodeoxycholic acid sodium 相关产品

•相关化合物库:

Natural Product Library Plus
Drug Repurposing Compound Library Plus
FDA-Approved Drug Library Plus
Bioactive Compound Library Plus
GPCR/G Protein Compound Library
Immunology/Inflammation Compound Library
Metabolism/Protease Compound Library
Natural Product Library
FDA-Approved Drug Library
Anti-Cancer Compound Library
Drug Repurposing Compound Library
Lipid Compound Library
Orally Active Compound Library
FDA Approved & Pharmacopeial Drug Library
Gut Microbial Metabolite Library
Microbial Metabolite Library
Anti-Obesity Compound Library
Lipid Metabolism Compound Library
Rare Diseases Drug Library

生物活性

Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active^[1]^[2].

IC₅₀ & Target

Microbial Metabolite

体内研究
(In Vivo)

Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) sodium results in weight loss in C57BL/6J wildtype mice^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week old C57BL/6J WT mice (male and female)^[1]
Dosage:	50, 150, and 450 mg/kg dissolved in corn oil
Administration:	Oral gavage; daily for 21 days
Result:	Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.

分子量

414.55

Formula

C₂₄H₃₉NaO₄

CAS 号

2898-95-5

中文名称

熊去氧胆酸钠盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

DMSO : 125 mg/mL (301.53 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4123 mL	12.0613 mL	24.1225 mL
5 mM	0.4825 mL	2.4123 mL	4.8245 mL
10 mM	0.2412 mL	1.2061 mL	2.4123 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18.

[2]. Goossens JF, et al. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy. Pharmacol Ther. 2019;203:107396.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ursodeoxycholic acid sodium(Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

发表于2024年12月10日由上海金畔生物科技有限公司

Ursodeoxycholic acid sodium (Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

Ursodeoxycholic acid sodium Chemical Structure

CAS No. : 2898-95-5

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
500 mg	￥1000	In-stock
1 g	￥1800	In-stock
5 g	￥6300	In-stock
10 g		询价
50 g		询价

* Please select Quantity before adding items.

Ursodeoxycholic acid sodium 相关产品

•相关化合物库:

Natural Product Library Plus
Drug Repurposing Compound Library Plus
FDA-Approved Drug Library Plus
Bioactive Compound Library Plus
GPCR/G Protein Compound Library
Immunology/Inflammation Compound Library
Metabolism/Protease Compound Library
Natural Product Library
FDA-Approved Drug Library
Anti-Cancer Compound Library
Drug Repurposing Compound Library
Lipid Compound Library
Orally Active Compound Library
FDA Approved & Pharmacopeial Drug Library
Gut Microbial Metabolite Library
Microbial Metabolite Library
Anti-Obesity Compound Library
Lipid Metabolism Compound Library
Rare Diseases Drug Library

生物活性

IC₅₀ & Target

Microbial Metabolite

体内研究
(In Vivo)

Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) sodium results in weight loss in C57BL/6J wildtype mice^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week old C57BL/6J WT mice (male and female)^[1]
Dosage:	50, 150, and 450 mg/kg dissolved in corn oil
Administration:	Oral gavage; daily for 21 days
Result:	Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.

分子量

414.55

Formula

C₂₄H₃₉NaO₄

CAS 号

2898-95-5

中文名称

熊去氧胆酸钠盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

DMSO : 125 mg/mL (301.53 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4123 mL	12.0613 mL	24.1225 mL
5 mM	0.4825 mL	2.4123 mL	4.8245 mL
10 mM	0.2412 mL	1.2061 mL	2.4123 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18.

[2]. Goossens JF, et al. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy. Pharmacol Ther. 2019;203:107396.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ursodeoxycholic acid sodium(Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

发表于2024年12月10日由上海金畔生物科技有限公司

Ursodeoxycholic acid sodium (Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

Ursodeoxycholic acid sodium Chemical Structure

CAS No. : 2898-95-5

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
500 mg	￥1000	In-stock
1 g	￥1800	In-stock
5 g	￥6300	In-stock
10 g		询价
50 g		询价

* Please select Quantity before adding items.

Ursodeoxycholic acid sodium 相关产品

•相关化合物库:

Natural Product Library Plus
Drug Repurposing Compound Library Plus
FDA-Approved Drug Library Plus
Bioactive Compound Library Plus
GPCR/G Protein Compound Library
Immunology/Inflammation Compound Library
Metabolism/Protease Compound Library
Natural Product Library
FDA-Approved Drug Library
Anti-Cancer Compound Library
Drug Repurposing Compound Library
Lipid Compound Library
Orally Active Compound Library
FDA Approved & Pharmacopeial Drug Library
Gut Microbial Metabolite Library
Microbial Metabolite Library
Anti-Obesity Compound Library
Lipid Metabolism Compound Library
Rare Diseases Drug Library

生物活性

IC₅₀ & Target

Microbial Metabolite

体内研究
(In Vivo)

Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) sodium results in weight loss in C57BL/6J wildtype mice^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week old C57BL/6J WT mice (male and female)^[1]
Dosage:	50, 150, and 450 mg/kg dissolved in corn oil
Administration:	Oral gavage; daily for 21 days
Result:	Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.

分子量

414.55

Formula

C₂₄H₃₉NaO₄

CAS 号

2898-95-5

中文名称

熊去氧胆酸钠盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

DMSO : 125 mg/mL (301.53 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4123 mL	12.0613 mL	24.1225 mL
5 mM	0.4825 mL	2.4123 mL	4.8245 mL
10 mM	0.2412 mL	1.2061 mL	2.4123 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.02 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18.

[2]. Goossens JF, et al. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy. Pharmacol Ther. 2019;203:107396.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ursodeoxycholic acid(Synonyms: 熊去氧胆酸; Ursodeoxycholate; Ursodiol; UDCA)

发表于2024年9月29日由上海金畔生物科技有限公司

Ursodeoxycholic acid (Synonyms: 熊去氧胆酸; Ursodeoxycholate; Ursodiol; UDCA) 纯度: ≥98.0%

Ursodeoxycholic acid (Ursodeoxycholate) 是由肠道细菌转化 (cheno)脱氧胆酸而产生的一种次级胆汁酸，是肠道屏障完整性的关键调节因子，对脂质代谢至关重要。Ursodeoxycholic acid 作为信号分子，通过与胆汁酸激活的受体相互作用发挥作用，包括G蛋白偶联的胆汁酸受体5 (TGR5，GPCR19) 和法尼酯X受体 (FXR)。Ursodeoxycholic acid 可用于多种肝脏和胃肠道疾病的研究。具有口服活性。

Ursodeoxycholic acid Chemical Structure

CAS No. : 128-13-2

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥350	In-stock
1 g	￥400	In-stock
5 g	￥930	In-stock
10 g		询价
50 g		询价

* Please select Quantity before adding items.

Ursodeoxycholic acid 相关产品

•相关化合物库:

Natural Product Library Plus
Drug Repurposing Compound Library Plus
FDA-Approved Drug Library Plus
FDA-Approved Drug Library Mini
Bioactive Compound Library Plus
GPCR/G Protein Compound Library
Metabolism/Protease Compound Library
Natural Product Library
FDA-Approved Drug Library
Anti-Cancer Compound Library
Human Endogenous Metabolite Compound Library
Drug Repurposing Compound Library
Orally Active Compound Library
FDA Approved & Pharmacopeial Drug Library
Drug-Induced Liver Injury (DILI) Compound Library
Anti-Obesity Compound Library
Lipid Metabolism Compound Library
Food-Sourced Compound Library
Rare Diseases Drug Library

生物活性

Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active^[1]^[2].

IC₅₀ & Target

Human Endogenous Metabolite

体内研究
(In Vivo)

Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) results in weight loss in C57BL/6J wildtype mice^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week old C57BL/6J WT mice (male and female)^[1]
Dosage:	50, 150, and 450 mg/kg dissolved in corn oil
Administration:	Oral gavage; daily for 21 days
Result:	Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.

Clinical Trial

分子量

392.57

Formula

C₂₄H₄₀O₄

CAS 号

128-13-2

中文名称

熊去氧胆酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (254.73 mM)

H₂O : 1 mg/mL (2.55 mM; ultrasonic and warming and heat to 80°C)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5473 mL	12.7366 mL	25.4732 mL
5 mM	0.5095 mL	2.5473 mL	5.0946 mL
10 mM	0.2547 mL	1.2737 mL	2.5473 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.30 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.30 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.30 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7.

[2]. Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14.

[3]. Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ursodeoxycholic acid-d5(Synonyms: Ursodiol-d5; UDCA-d5)

发表于2024年4月10日由上海金畔生物科技有限公司

Ursodeoxycholic acid-d5 (Synonyms: Ursodiol-d5; UDCA-d5)

Ursodeoxycholic acid-d5 (Ursodiol-d5) 是 Ursodeoxycholic acid 的氘代物。Ursodeoxycholic acid (Ursodeoxycholate) 是由肠道细菌转化 (cheno)脱氧胆酸而产生的一种次级胆汁酸，是肠道屏障完整性的关键调节因子，对脂质代谢至关重要。Ursodeoxycholic acid 作为信号分子，通过与胆汁酸激活的受体相互作用发挥作用，包括G蛋白偶联的胆汁酸受体5 (TGR5，GPCR19) 和法尼酯X受体 (FXR)。Ursodeoxycholic acid 可用于多种肝脏和胃肠道疾病的研究。具有口服活性。

Ursodeoxycholic acid-d5 Chemical Structure

CAS No. : 93701-18-9

规格		是否有货
2.5 mg		Check price and availability
1 mg		Check price and availability
5 mg		Check price and availability
10 mg		Check price and availability

* Please select Quantity before adding items.

生物活性	Ursodeoxycholic acid-d5 (Ursodiol-d5) is the deuterium labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active^[1]^[2].
体外研究 (In Vitro)	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量	397.60
Formula	C₂₄H₃₅D₅O₄
CAS 号	93701-18-9
中文名称	熊去氧胆酸 d5
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7. [3]. Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14. [4]. Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

whatman (沃特曼)

英国沃特曼 Millipore PALL中国代理商金畔官网

标签归档：ursodeoxycholic

Ursodeoxycholic acid sodium(Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

Ursodeoxycholic acid sodium 相关产品

•相关化合物库:

Ursodeoxycholic acid sodium(Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

Ursodeoxycholic acid sodium 相关产品

•相关化合物库:

Ursodeoxycholic acid sodium(Synonyms: 熊去氧胆酸钠盐; Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

Ursodeoxycholic acid sodium 相关产品

•相关化合物库:

Ursodeoxycholic acid(Synonyms: 熊去氧胆酸; Ursodeoxycholate; Ursodiol; UDCA)

Ursodeoxycholic acid 相关产品

•相关化合物库:

Ursodeoxycholic acid-d5(Synonyms: Ursodiol-d5; UDCA-d5)

2025年 5月
一	二	三	四	五	六	日
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31